转移性乳腺癌的⁶⁸Ga-PSMA成像。 - Suppr

⁶⁸Ga-PSMA imaging of metastatic breast cancer.

作者信息

Sathekge Mike, Modiselle Moshe, Vorster Mariza, Mokgoro Neo, Nyakale Nozipho, Mokaleng Brenda, Ebenhan Thomas

机构信息

Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Private Bag X169, Pretoria, 0001, South Africa,

出版信息

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1482-3. doi: 10.1007/s00259-015-3066-x. Epub 2015 May 1.

DOI:10.1007/s00259-015-3066-x

PMID:25931036

Abstract

摘要

相似文献

⁶⁸Ga-PSMA imaging of metastatic breast cancer.

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1482-3. doi: 10.1007/s00259-015-3066-x. Epub 2015 May 1.

(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1461-2. doi: 10.1007/s00259-014-2766-y. Epub 2014 Apr 23.

Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):193-194. doi: 10.1007/s00259-015-3235-y. Epub 2015 Oct 27.

Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT.

Clin Nucl Med. 2015 Sep;40(9):755-6. doi: 10.1097/RLU.0000000000000870.

Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):195-196. doi: 10.1007/s00259-015-3236-x. Epub 2015 Oct 27.

Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer.

Clin Nucl Med. 2016 Feb;41(2):159-60. doi: 10.1097/RLU.0000000000001058.

PSMA PET in Prostate Cancer.

J Nucl Med. 2015 Aug;56(8):1131-2. doi: 10.2967/jnumed.115.157339. Epub 2015 May 14.

(68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):795-6. doi: 10.1007/s00259-015-3297-x. Epub 2016 Jan 8.

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20.

Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT.

Clin Nucl Med. 2015 Feb;40(2):e163-6. doi: 10.1097/RLU.0000000000000594.

引用本文的文献

Unveiling Prostate-Specific Membrane Antigen's Potential in Breast Cancer Management.

Cancers (Basel). 2025 Jan 28;17(3):456. doi: 10.3390/cancers17030456.

Currents status of radiotracers for breast cancer imaging in PET.

Transl Oncol. 2025 Mar;53:102304. doi: 10.1016/j.tranon.2025.102304. Epub 2025 Feb 7.

Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.

Int J Mol Sci. 2024 Jan 26;25(3):1575. doi: 10.3390/ijms25031575.

The Role of PET/CT in Breast Cancer.

Diagnostics (Basel). 2023 Feb 6;13(4):597. doi: 10.3390/diagnostics13040597.

Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer.

Cancers (Basel). 2022 Apr 23;14(9):2103. doi: 10.3390/cancers14092103.

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.

Front Med (Lausanne). 2022 Apr 12;9:881551. doi: 10.3389/fmed.2022.881551. eCollection 2022.

Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer.

Geburtshilfe Frauenheilkd. 2022 Jan 10;82(1):50-58. doi: 10.1055/a-1638-9429. eCollection 2022 Jan.

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.

Eur J Nucl Med Mol Imaging. 2021 May;48(5):1626-1638. doi: 10.1007/s00259-021-05245-y. Epub 2021 Feb 19.

Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.

Cells. 2020 Oct 21;9(10):2334. doi: 10.3390/cells9102334.

Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.

Asia Ocean J Nucl Med Biol. 2020 Spring;8(2):136-140. doi: 10.22038/AOJNMB.2020.46939.1314.

本文引用的文献

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20.

(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1461-2. doi: 10.1007/s00259-014-2766-y. Epub 2014 Apr 23.

Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.

Cancer Cell Int. 2014 Mar 20;14(1):26. doi: 10.1186/1475-2867-14-26.

Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.

APMIS. 2014 Jun;122(6):482-9. doi: 10.1111/apm.12195. Epub 2013 Dec 5.

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20. doi: 10.1007/s00259-013-2525-5. Epub 2013 Sep 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

⁶⁸Ga-PSMA imaging of metastatic breast cancer.

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1482-3. doi: 10.1007/s00259-015-3066-x. Epub 2015 May 1.

(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1461-2. doi: 10.1007/s00259-014-2766-y. Epub 2014 Apr 23.

Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):193-194. doi: 10.1007/s00259-015-3235-y. Epub 2015 Oct 27.

Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT.

Clin Nucl Med. 2015 Sep;40(9):755-6. doi: 10.1097/RLU.0000000000000870.

Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):195-196. doi: 10.1007/s00259-015-3236-x. Epub 2015 Oct 27.

Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer.

Clin Nucl Med. 2016 Feb;41(2):159-60. doi: 10.1097/RLU.0000000000001058.

PSMA PET in Prostate Cancer.

J Nucl Med. 2015 Aug;56(8):1131-2. doi: 10.2967/jnumed.115.157339. Epub 2015 May 14.

(68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.

Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):795-6. doi: 10.1007/s00259-015-3297-x. Epub 2016 Jan 8.

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20.

Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT.

Clin Nucl Med. 2015 Feb;40(2):e163-6. doi: 10.1097/RLU.0000000000000594.

引用本文的文献

Unveiling Prostate-Specific Membrane Antigen's Potential in Breast Cancer Management.

Cancers (Basel). 2025 Jan 28;17(3):456. doi: 10.3390/cancers17030456.

Currents status of radiotracers for breast cancer imaging in PET.

Transl Oncol. 2025 Mar;53:102304. doi: 10.1016/j.tranon.2025.102304. Epub 2025 Feb 7.

Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.

Int J Mol Sci. 2024 Jan 26;25(3):1575. doi: 10.3390/ijms25031575.

The Role of PET/CT in Breast Cancer.

Diagnostics (Basel). 2023 Feb 6;13(4):597. doi: 10.3390/diagnostics13040597.

Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer.

Cancers (Basel). 2022 Apr 23;14(9):2103. doi: 10.3390/cancers14092103.

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.

Front Med (Lausanne). 2022 Apr 12;9:881551. doi: 10.3389/fmed.2022.881551. eCollection 2022.

Expression of Prostate Specific Membrane Antigen (PSMA) in Breast Cancer.

Geburtshilfe Frauenheilkd. 2022 Jan 10;82(1):50-58. doi: 10.1055/a-1638-9429. eCollection 2022 Jan.

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.

Eur J Nucl Med Mol Imaging. 2021 May;48(5):1626-1638. doi: 10.1007/s00259-021-05245-y. Epub 2021 Feb 19.

Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.

Cells. 2020 Oct 21;9(10):2334. doi: 10.3390/cells9102334.

Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.

Asia Ocean J Nucl Med Biol. 2020 Spring;8(2):136-140. doi: 10.22038/AOJNMB.2020.46939.1314.

本文引用的文献

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. doi: 10.1007/s00259-014-2949-6. Epub 2014 Nov 20.

(68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1461-2. doi: 10.1007/s00259-014-2766-y. Epub 2014 Apr 23.

Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.

Cancer Cell Int. 2014 Mar 20;14(1):26. doi: 10.1186/1475-2867-14-26.

Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.

APMIS. 2014 Jun;122(6):482-9. doi: 10.1111/apm.12195. Epub 2013 Dec 5.

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20. doi: 10.1007/s00259-013-2525-5. Epub 2013 Sep 27.

⁶⁸Ga-PSMA imaging of metastatic breast cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献